Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show bene...

Descrición completa

Detalles Bibliográficos
Main Authors: Schilling, WHK, Mukaka, M, Callery, JJ, Llewelyn, MJ, Cruz, CV, Dhorda, M, Ngernseng, T, Waithira, N, Ekkapongpisit, M, Watson, JA, Chandna, A, Nelwan, EJ, Hamers, RL, Etyang, A, Beg, MA, Sow, S, Yavo, W, Allabi, AC, Basnyat, B, Sharma, SK, Amofa-Sekyi, M, Yonga, P, Adler, A, Yuentrakul, P, Abdad, MY, Blacksell, SD, Tarning, J, Rahardjani, M, Rimainar, A, Akech, S, Hamaluba, M, Shrestha, S, Rijal, S, Woodrow, CJ, Cheah, PY, Taylor, WRJ, Batty, EM, von Seidlein, L, Dondorp, A, Day, NPJ, White, NJ
Formato: Journal article
Idioma:English
Publicado: Public Library of Science 2024
_version_ 1826314508692357120
author Schilling, WHK
Mukaka, M
Callery, JJ
Llewelyn, MJ
Cruz, CV
Dhorda, M
Ngernseng, T
Waithira, N
Ekkapongpisit, M
Watson, JA
Chandna, A
Nelwan, EJ
Hamers, RL
Etyang, A
Beg, MA
Sow, S
Yavo, W
Allabi, AC
Basnyat, B
Sharma, SK
Amofa-Sekyi, M
Yonga, P
Adler, A
Yuentrakul, P
Abdad, MY
Blacksell, SD
Tarning, J
Rahardjani, M
Rimainar, A
Akech, S
Hamaluba, M
Shrestha, S
Rijal, S
Woodrow, CJ
Cheah, PY
Taylor, WRJ
Batty, EM
von Seidlein, L
Dondorp, A
Day, NPJ
White, NJ
author_facet Schilling, WHK
Mukaka, M
Callery, JJ
Llewelyn, MJ
Cruz, CV
Dhorda, M
Ngernseng, T
Waithira, N
Ekkapongpisit, M
Watson, JA
Chandna, A
Nelwan, EJ
Hamers, RL
Etyang, A
Beg, MA
Sow, S
Yavo, W
Allabi, AC
Basnyat, B
Sharma, SK
Amofa-Sekyi, M
Yonga, P
Adler, A
Yuentrakul, P
Abdad, MY
Blacksell, SD
Tarning, J
Rahardjani, M
Rimainar, A
Akech, S
Hamaluba, M
Shrestha, S
Rijal, S
Woodrow, CJ
Cheah, PY
Taylor, WRJ
Batty, EM
von Seidlein, L
Dondorp, A
Day, NPJ
White, NJ
author_sort Schilling, WHK
collection OXFORD
description Background: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings: Healthy adult participants from the healthcare setting, and later from the community, were enrolled in 26 centres in 11 countries to a double-blind, placebo-controlled, randomised trial of COVID-19 chemoprevention. HCQ was evaluated in Europe and Africa, and chloroquine (CQ) was evaluated in Asia, (both base equivalent of 155 mg once daily). The primary endpoint was symptomatic COVID-19, confirmed by PCR or seroconversion during the 3-month follow-up period. The secondary and tertiary endpoints were: asymptomatic laboratory-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; severity of COVID-19 symptoms; all-cause PCR-confirmed symptomatic acute respiratory illness (including SARS-CoV-2 infection); participant reported number of workdays lost; genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity (not reported here); and health economic analyses of HCQ and CQ prophylaxis on costs and quality of life measures (not reported here). The primary and safety analyses were conducted in the intention-to-treat (ITT) population. Recruitment of 40,000 (20,000 HCQ arm, 20,000 CQ arm) participants was planned but was not possible because of protracted delays resulting from controversies over efficacy and adverse events with HCQ use, vaccine rollout in some countries, and other factors. Between 29 April 2020 and 10 March 2022, 4,652 participants (46% females) were enrolled (HCQ/CQ n = 2,320; placebo n = 2,332). The median (IQR) age was 29 (23 to 39) years. SARS-CoV-2 infections (symptomatic and asymptomatic) occurred in 1,071 (23%) participants. For the primary endpoint the incidence of symptomatic COVID-19 was 240/2,320 in the HCQ/CQ versus 284/2,332 in the placebo arms (risk ratio (RR) 0.85 [95% confidence interval, 0.72 to 1.00; p = 0.05]). For the secondary and tertiary outcomes asymptomatic SARS-CoV-2 infections occurred in 11.5% of HCQ/CQ recipients and 12.0% of placebo recipients: RR: 0.96 (95% CI, 0.82 to 1.12; p = 0.6). There were no differences in the severity of symptoms between the groups and no severe illnesses. HCQ/CQ chemoprevention was associated with fewer PCR-confirmed all-cause respiratory infections (predominantly SARS-CoV-2): RR 0.61 (95% CI, 0.42 to 0.88; p = 0.009) and fewer days lost to work because of illness: 104 days per 1,000 participants over 90 days (95% CI, 12 to 199 days; p < 0.001). The prespecified meta-analysis of all published pre-exposure RCTs indicates that HCQ/CQ prophylaxis provided a moderate protective benefit against symptomatic COVID-19: RR 0.80 (95% CI, 0.71 to 0.91). Both drugs were well tolerated with no drug-related serious adverse events (SAEs). Study limitations include the smaller than planned study size, the relatively low number of PCR-confirmed infections, and the lower comparative accuracy of serology endpoints (in particular, the adapted dried blood spot method) compared to the PCR endpoint. The COPCOV trial was registered with ClinicalTrials.gov; number NCT04303507. Interpretation: In this large placebo-controlled, double-blind randomised trial, HCQ and CQ were safe and well tolerated in COVID-19 chemoprevention, and there was evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs. Trial registration: ClinicalTrials.gov NCT04303507; ISRCTN Registry ISRCTN10207947.
first_indexed 2024-09-25T04:35:09Z
format Journal article
id oxford-uuid:7e3e444e-faa3-4bb4-a1c1-b3de1da3d6ed
institution University of Oxford
language English
last_indexed 2024-09-25T04:35:09Z
publishDate 2024
publisher Public Library of Science
record_format dspace
spelling oxford-uuid:7e3e444e-faa3-4bb4-a1c1-b3de1da3d6ed2024-09-13T20:10:28ZEvaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7e3e444e-faa3-4bb4-a1c1-b3de1da3d6edEnglishJisc Publications RouterPublic Library of Science2024Schilling, WHKMukaka, MCallery, JJLlewelyn, MJCruz, CVDhorda, MNgernseng, TWaithira, NEkkapongpisit, MWatson, JAChandna, ANelwan, EJHamers, RLEtyang, ABeg, MASow, SYavo, WAllabi, ACBasnyat, BSharma, SKAmofa-Sekyi, MYonga, PAdler, AYuentrakul, PAbdad, MYBlacksell, SDTarning, JRahardjani, MRimainar, AAkech, SHamaluba, MShrestha, SRijal, SWoodrow, CJCheah, PYTaylor, WRJBatty, EMvon Seidlein, LDondorp, ADay, NPJWhite, NJBackground: Hydroxychloroquine (HCQ) has proved ineffective in treating patients hospitalised with Coronavirus Disease 2019 (COVID-19), but uncertainty remains over its safety and efficacy in chemoprevention. Previous chemoprevention randomised controlled trials (RCTs) did not individually show benefit of HCQ against COVID-19 and, although meta-analysis did suggest clinical benefit, guidelines recommend against its use. Methods and findings: Healthy adult participants from the healthcare setting, and later from the community, were enrolled in 26 centres in 11 countries to a double-blind, placebo-controlled, randomised trial of COVID-19 chemoprevention. HCQ was evaluated in Europe and Africa, and chloroquine (CQ) was evaluated in Asia, (both base equivalent of 155 mg once daily). The primary endpoint was symptomatic COVID-19, confirmed by PCR or seroconversion during the 3-month follow-up period. The secondary and tertiary endpoints were: asymptomatic laboratory-confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; severity of COVID-19 symptoms; all-cause PCR-confirmed symptomatic acute respiratory illness (including SARS-CoV-2 infection); participant reported number of workdays lost; genetic and baseline biochemical markers associated with symptomatic COVID-19, respiratory illness and disease severity (not reported here); and health economic analyses of HCQ and CQ prophylaxis on costs and quality of life measures (not reported here). The primary and safety analyses were conducted in the intention-to-treat (ITT) population. Recruitment of 40,000 (20,000 HCQ arm, 20,000 CQ arm) participants was planned but was not possible because of protracted delays resulting from controversies over efficacy and adverse events with HCQ use, vaccine rollout in some countries, and other factors. Between 29 April 2020 and 10 March 2022, 4,652 participants (46% females) were enrolled (HCQ/CQ n = 2,320; placebo n = 2,332). The median (IQR) age was 29 (23 to 39) years. SARS-CoV-2 infections (symptomatic and asymptomatic) occurred in 1,071 (23%) participants. For the primary endpoint the incidence of symptomatic COVID-19 was 240/2,320 in the HCQ/CQ versus 284/2,332 in the placebo arms (risk ratio (RR) 0.85 [95% confidence interval, 0.72 to 1.00; p = 0.05]). For the secondary and tertiary outcomes asymptomatic SARS-CoV-2 infections occurred in 11.5% of HCQ/CQ recipients and 12.0% of placebo recipients: RR: 0.96 (95% CI, 0.82 to 1.12; p = 0.6). There were no differences in the severity of symptoms between the groups and no severe illnesses. HCQ/CQ chemoprevention was associated with fewer PCR-confirmed all-cause respiratory infections (predominantly SARS-CoV-2): RR 0.61 (95% CI, 0.42 to 0.88; p = 0.009) and fewer days lost to work because of illness: 104 days per 1,000 participants over 90 days (95% CI, 12 to 199 days; p < 0.001). The prespecified meta-analysis of all published pre-exposure RCTs indicates that HCQ/CQ prophylaxis provided a moderate protective benefit against symptomatic COVID-19: RR 0.80 (95% CI, 0.71 to 0.91). Both drugs were well tolerated with no drug-related serious adverse events (SAEs). Study limitations include the smaller than planned study size, the relatively low number of PCR-confirmed infections, and the lower comparative accuracy of serology endpoints (in particular, the adapted dried blood spot method) compared to the PCR endpoint. The COPCOV trial was registered with ClinicalTrials.gov; number NCT04303507. Interpretation: In this large placebo-controlled, double-blind randomised trial, HCQ and CQ were safe and well tolerated in COVID-19 chemoprevention, and there was evidence of moderate protective benefit in a meta-analysis including this trial and similar RCTs. Trial registration: ClinicalTrials.gov NCT04303507; ISRCTN Registry ISRCTN10207947.
spellingShingle Schilling, WHK
Mukaka, M
Callery, JJ
Llewelyn, MJ
Cruz, CV
Dhorda, M
Ngernseng, T
Waithira, N
Ekkapongpisit, M
Watson, JA
Chandna, A
Nelwan, EJ
Hamers, RL
Etyang, A
Beg, MA
Sow, S
Yavo, W
Allabi, AC
Basnyat, B
Sharma, SK
Amofa-Sekyi, M
Yonga, P
Adler, A
Yuentrakul, P
Abdad, MY
Blacksell, SD
Tarning, J
Rahardjani, M
Rimainar, A
Akech, S
Hamaluba, M
Shrestha, S
Rijal, S
Woodrow, CJ
Cheah, PY
Taylor, WRJ
Batty, EM
von Seidlein, L
Dondorp, A
Day, NPJ
White, NJ
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
title Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
title_full Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
title_fullStr Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
title_full_unstemmed Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
title_short Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
title_sort evaluation of hydroxychloroquine or chloroquine for the prevention of covid 19 copcov a double blind randomised placebo controlled trial
work_keys_str_mv AT schillingwhk evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT mukakam evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT calleryjj evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT llewelynmj evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT cruzcv evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT dhordam evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT ngernsengt evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT waithiran evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT ekkapongpisitm evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT watsonja evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT chandnaa evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT nelwanej evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT hamersrl evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT etyanga evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT begma evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT sows evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT yavow evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT allabiac evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT basnyatb evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT sharmask evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT amofasekyim evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT yongap evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT adlera evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT yuentrakulp evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT abdadmy evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT blacksellsd evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT tarningj evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT rahardjanim evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT rimainara evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT akechs evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT hamalubam evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT shresthas evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT rijals evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT woodrowcj evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT cheahpy evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT taylorwrj evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT battyem evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT vonseidleinl evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT dondorpa evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT daynpj evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial
AT whitenj evaluationofhydroxychloroquineorchloroquineforthepreventionofcovid19copcovadoubleblindrandomisedplacebocontrolledtrial